Business Wire

CT-XEROX

25.6.2020 14:39:04 CEST | Business Wire | Press release

Share
New Xerox Team Availability App Supports Flexible Workplace Needs

Today, Xerox announced the launch of its Team Availability App , a quick-to-deploy, real-time solution for organizations that need to understand employee availability and location. Knowing where and whether employees are working is critical to managing flexible work environments, where the percentage of employees sharing time between home and work locations grows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005437/en/

Organizations are actively supporting and investing in technology solutions for a hybrid workforce. A recent global business survey commissioned by Xerox shows 58% of respondents plan to change their work from home policy within the next year. This new acceptance of a hybrid workforce has also revealed technology gaps, with companies increasing investment in remote technology resources (55%) or a hybrid of remote and in-office resources (40%).

"Managing a distributed workforce during a continued pandemic presents unique challenges no organization has experienced before," said Joanne Collins Smee, executive vice president and chief commercial, SMB and channels officer, Xerox. "Organizations need to know who is available and where so they can make better decisions when allocating resources and work. This tool provides real-time knowledge to managers with distributed employee populations."

Unlike other attendance management tools, which need to plug into IT infrastructure and take weeks to implement, the Team Availability App is ready in just hours. Once populated, the app provides authorized users with customizable and privacy-protected data for strategic decision making. Xerox is rolling out the app across the company to support its Path Forward plans to manage a phased approach to returning to the workplace safely. Xerox is leveraging the app with its own employee population to conduct daily health checks for exposure related to COVID-19. Tracking of this activity allows for a safe and phased return to the workplace.

The U.K.'s prestigious Imperial NHS Trust was the first organization to pilot the Xerox Team Availability App to access the status of essential workers across the Trust and its newly assigned locations at the height of the pandemic.

"It's important for a healthcare provider to know which caregivers are available when to support patients, and that's even more critical in a pandemic," said Linda Watts, joint clinical systems program manager, Imperial NHS Trust & Chelsea & Westminster NHS Foundation Trust, head of health records, Imperial College Healthcare NHS Trust. "The Xerox Team Availability App was deployed at lightning speed, and we got updates from staff on their availability in real-time. As a result, we could always make sure our patients were covered."

The Xerox Team Availability App is a GDPR-compliant SaaS offering with a subscription-based model that allows customers to sign up for as long as required. It's available now on the App Store and Google Play Store .

For more information and additional results from the Xerox Future of Work study, visit www.Xerox.com/MakeNowWork .

About Xerox

Xerox makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, the ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com .

Xerox Future of Work Survey Methodology

The survey of 600 respondents located in the U.S., Canada, UK, Germany and France was conducted by independent research firm Vanson Bourne in May 2020. Respondents included IT decision-makers (including senior C-level professionals), all from organizations with at least 500 employees across a range of sectors, including business and professional services, retail, health care, financial services, and travel and hospitality.

Note: To receive RSS news feeds, visit https://www.news.xerox.com . For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp , https://www.instagram.com/xerox/ , http://www.linkedin.com/company/xerox , http://www.youtube.com/XeroxCorp .

Xerox® is a trademark of Xerox Corporation in the United States and/or other countries.

Link:

ClickThru

Social Media:

https://www.facebook.com/XeroxCorp/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye